Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers

Headache

Volumn 40, Issue 2, 2000, Pages 158-163

  Sheftell, Fred ^a   Rapoport, A ^a   Weeks, R ^a   Walker, B ^a   Gammerman, I ^a   Baskin, S ^a  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

Leukotrienes; Migraine; Montelukast

Indexed keywords

LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ZAFIRLUKAST; ZILEUTON;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MIGRAINE; PRIORITY JOURNAL; PROPHYLAXIS;

ACETATES; ADOLESCENT; ADULT; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; QUINOLINES;

EID: 0034051612     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2000.00022.x     Document Type: Article

References (24)

1. Parantainen J, Vapaatalo H, Hokkanen E. Clinical aspects of prostaglandins and leukotrienes in migraine. Cephalalgia. 1986;6(suppl 4):95-101.
2. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med. 1993;44:145-154.
3. Wolfe S. Prostacyclin and prostaglandins and their possible role in migraine. Headache. 1979;19:245.
4. Horrohin DF. Hypothesis: prostaglandins and migraine. Headache. 1977;17:113-117.
5. Siegel MI. Effect of non-steroidal anti-inflammatory drugs on arachidonic acid metabolism. Headache. 1981;21:264-271.
6. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974;26:33-67.
7. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs. 1994;47:12-24.
8. Metters KM. Leukotriene receptors. J Lipid Mediat Cell Signal. 1995;12:413-427.
9. Zileuton [package insert]. Abbott Laboratories.
10. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway [published correction appears in N Engl J Med. 1999;340:663]. N Engl J Med. 1999;340:197-206.
11. Zafirlukast [package insert]. Zeneca Pharmaceuticals.
12. Montelukast [package insert]. Merck & Company.
13. 4 generation by polymorphonuclear leukocytes: possible involvement in the pathogenesis of headache. Headache. 1986;26:460-464.
14. LaMancusa R, Pulcinelli FM, Ferroni P, et al. Blood leukotrienes in headache: correlation with platelet activity. Headache. 1991;31:409-414.
15. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol. 1992;43:2313-2320.
16. Vapaatalo H. Tolfenamic acid and migraine - aspects on prostaglandins and leukotrienes. Pharmacol Toxicol. 1994;75(suppl 2):76-80.
17. Moskowitz MA. Basic mechanisms in vascular headache. Neural Clin. 1990;8:801-815.
18. Ledwozyw A, Kadziolka A. Effects of nifedipine and verapamil on cysteinyl leukotriene-induced contractions of the sheep uterus [in Polish]. Pol Arch Weter. 1989;29:189-200.
19. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7);10-73.
21. Solomon GD. Circadian variation in the frequency of migraine. Cephalalgia. 1991;11(suppl 11):178-180.
22. Tfelt-Hansen P, Bousser MG, Solomon S, et al. Guidelines for controlled trials of drugs in migraine. In: Members' Handbook. International Headache Society. Oslo, Norway: Scandinavian University Press; 1998-1999:111-133.
23. Olness K, Hall H. Rozniecki JJ, Schmidt W, Theoharides TC. Mast cell activation in children with migraine before and after training in self-regulation. Headache. 1999;39:101-107.
24. Theoharides TC, Spanos C, Pang X, et al. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology. 1995;136:5745-5750.